Enfusion, Inc.
ENFN · NYSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -21.38 | 23.72 | -0.25 | 2.08 |
| FCF Yield | 0.72% | 1.52% | 0.59% | -0.15% |
| EV / EBITDA | 591.37 | 146.79 | 136.22 | 518.66 |
| Quality | ||||
| ROIC | 0.06% | 1.65% | 2.07% | -1.01% |
| Gross Margin | 69.02% | 68.06% | 67.72% | 66.34% |
| Cash Conversion Ratio | 56.24 | 6.58 | 4.01 | -2.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.27% | 11.26% | 12.70% | 14.34% |
| Free Cash Flow Growth | -47.64% | 190.52% | 479.26% | -138.69% |
| Safety | ||||
| Net Debt / EBITDA | -21.57 | -4.67 | -2.95 | -11.17 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 49.62 | 50.12 | 56.68 | 39.22 |